{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T11:07:05Z","timestamp":1785668825589,"version":"3.56.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Obes Rep"],"DOI":"10.1007\/s13679-025-00681-5","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T08:00:49Z","timestamp":1768291249000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacological Management of Diabesity: Current and Emerging Therapies"],"prefix":"10.1007","volume":"15","author":[{"given":"Martina","family":"Galasso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Caporusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Volatile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Verde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Giorgino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastio","family":"Perrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Colao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Barrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Muscogiuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of Obesity Programs of nutrition, Education, Research and Assessment (OPERA) Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"681_CR1","doi-asserted-by":"publisher","first-page":"1161521","DOI":"10.3389\/fendo.2023.1161521","volume":"14","author":"R Ruze","year":"2023","unstructured":"Ruze R, et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol (Lausanne). 2023;14:1161521.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"681_CR2","doi-asserted-by":"crossref","unstructured":"Chandrasekaran P, Weiskirchen R. The role of obesity in type 2 diabetes Mellitus-An overview. Int J Mol Sci. 2024;25(3):1882.","DOI":"10.3390\/ijms25031882"},{"issue":"6","key":"681_CR3","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/ijcp.12384","volume":"68","author":"JP Wilding","year":"2014","unstructured":"Wilding JP. The importance of weight management in type 2 diabetes mellitus. Int J Clin Pract. 2014;68(6):682\u201391.","journal-title":"Int J Clin Pract"},{"issue":"3","key":"681_CR4","doi-asserted-by":"publisher","first-page":"C375","DOI":"10.1152\/ajpcell.00379.2020","volume":"320","author":"T Kawai","year":"2021","unstructured":"Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol. 2021;320(3):C375\u201391.","journal-title":"Am J Physiol Cell Physiol"},{"key":"681_CR5","doi-asserted-by":"publisher","first-page":"103363","DOI":"10.1016\/j.eclinm.2025.103363","volume":"86","author":"A Moiz","year":"2025","unstructured":"Moiz A, et al. The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions. EClinicalMedicine. 2025;86:103363.","journal-title":"EClinicalMedicine"},{"issue":"21","key":"681_CR6","first-page":"2099","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(21):2099.","journal-title":"N Engl J Med"},{"key":"681_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","volume":"30","author":"TD Muller","year":"2019","unstructured":"Muller TD, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72\u2013130.","journal-title":"Mol Metab"},{"issue":"2","key":"681_CR8","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","volume":"106","author":"MK Thomas","year":"2021","unstructured":"Thomas MK, et al. Dual GIP and GLP-1 receptor agonist Tirzepatide improves Beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab. 2021;106(2):388\u201396.","journal-title":"J Clin Endocrinol Metab"},{"key":"681_CR9","doi-asserted-by":"publisher","first-page":"1085799","DOI":"10.3389\/fendo.2023.1085799","volume":"14","author":"JY Wang","year":"2023","unstructured":"Wang JY, et al. GLP-1 receptor agonists for the treatment of obesity: role as a promising approach. Front Endocrinol (Lausanne). 2023;14:1085799.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"681_CR10","unstructured":"Administration USFD. Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors. 2018 [cited 2025 31 ottobre ]; Available from: https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/sodium-glucose-cotransporter-2-sglt2-inhibitors"},{"issue":"9","key":"681_CR11","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/dom.12127","volume":"15","author":"HJ Lambers Heerspink","year":"2013","unstructured":"Lambers Heerspink HJ, et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15(9):853\u201362.","journal-title":"Diabetes Obes Metab"},{"key":"681_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.diabres.2018.01.004","volume":"137","author":"D El Masri","year":"2018","unstructured":"El Masri D, Ghosh S, Jaber LA. Safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2018;137:83\u201392.","journal-title":"Diabetes Res Clin Pract"},{"issue":"9","key":"681_CR13","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1111\/dom.14075","volume":"22","author":"J Liu","year":"2020","unstructured":"Liu J, et al. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2020;22(9):1619\u201327.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"681_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12933-021-01213-w","volume":"20","author":"D Giugliano","year":"2021","unstructured":"Giugliano D, et al. Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes. Cardiovasc Diabetol. 2021;20(1):17.","journal-title":"Cardiovasc Diabetol"},{"key":"681_CR15","doi-asserted-by":"publisher","first-page":"104215","DOI":"10.1016\/j.ebiom.2022.104215","volume":"83","author":"YM Gao","year":"2022","unstructured":"Gao YM, et al. Cardiorenal protection of SGLT2 inhibitors-Perspectives from metabolic reprogramming. EBioMedicine. 2022;83:104215.","journal-title":"EBioMedicine"},{"issue":"1 Suppl 1","key":"681_CR16","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.2337\/dc25-S009","volume":"48","author":"American Diabetes Association Professional Practice","year":"2025","unstructured":"American Diabetes Association Professional Practice. 9. Pharmacologic approaches to glycemic treatment: standards of care in Diabetes-2025. Diabetes Care. 2025;48(1 Suppl 1):S181\u2013206.","journal-title":"Diabetes Care"},{"issue":"6 Suppl 1","key":"681_CR17","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/S1262-3636(14)72693-X","volume":"40","author":"S Halimi","year":"2014","unstructured":"Halimi S, Verges B. Adverse effects and safety of SGLT-2 inhibitors. Diabetes Metab. 2014;40(6 Suppl 1):S28\u201334.","journal-title":"Diabetes Metab"},{"issue":"12","key":"681_CR18","doi-asserted-by":"publisher","first-page":"e0279889","DOI":"10.1371\/journal.pone.0279889","volume":"17","author":"R Pan","year":"2022","unstructured":"Pan R, et al. Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. PLoS ONE. 2022;17(12):e0279889.","journal-title":"PLoS ONE"},{"issue":"10","key":"681_CR19","first-page":"e72771","volume":"16","author":"S Naeem","year":"2024","unstructured":"Naeem S, et al. Effects of Sodium-Glucose cotransporter 2 inhibitors on body Weight, BMI, and body composition in adults with type 2 diabetes mellitus: A systematic review. Cureus. 2024;16(10):e72771.","journal-title":"Cureus"},{"key":"681_CR20","doi-asserted-by":"publisher","first-page":"107787","DOI":"10.1016\/j.diabres.2019.107787","volume":"155","author":"K Esposito","year":"2019","unstructured":"Esposito K, et al. Metabolic effectiveness of Gliflozins and gliptins in the routine clinical practice of patients with type 2 diabetes: preliminary results from GIOIA, a prospective multicentre study. Diabetes Res Clin Pract. 2019;155:107787.","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"681_CR21","doi-asserted-by":"publisher","first-page":"216","DOI":"10.4183\/aeb.2022.216","volume":"18","author":"KG Pratama","year":"2022","unstructured":"Pratama KG, Tandarto K, Hengky A. Weight loss effect of Sodium-Glucose Cotransporter-2 (Sglt2) inhibitors in patients with obesity without diabetes: A systematic review. Acta Endocrinol (Buchar). 2022;18(2):216\u201324.","journal-title":"Acta Endocrinol (Buchar)"},{"issue":"2","key":"681_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/dom.12578","volume":"18","author":"SP Rajeev","year":"2016","unstructured":"Rajeev SP, Cuthbertson DJ, Wilding JP. Energy balance and metabolic changes with sodium-glucose co-transporter 2 Inhibition. Diabetes Obes Metab. 2016;18(2):125\u201334.","journal-title":"Diabetes Obes Metab"},{"key":"681_CR23","doi-asserted-by":"publisher","first-page":"1115321","DOI":"10.3389\/fendo.2023.1115321","volume":"14","author":"X Liu","year":"2023","unstructured":"Liu X, et al. The effects of Sodium-glucose cotransporter 2 inhibitors on adipose tissue in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2023;14:1115321.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"681_CR24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13098-023-01085-y","volume":"15","author":"X Wang","year":"2023","unstructured":"Wang X, et al. Effects of SGLT-2 inhibitors on adipose tissue distribution in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2023;15(1):113.","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"681_CR25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2337\/diaclin.32.1.4","volume":"32","author":"EC Chao","year":"2014","unstructured":"Chao EC. SGLT-2 inhibitors: A new mechanism for glycemic control. Clin Diabetes. 2014;32(1):4\u201311.","journal-title":"Clin Diabetes"},{"issue":"1","key":"681_CR26","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12933-021-01401-8","volume":"20","author":"MI Maiorino","year":"2021","unstructured":"Maiorino MI, et al. Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression. Cardiovasc Diabetol. 2021;20(1):210.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"681_CR27","doi-asserted-by":"publisher","first-page":"586","DOI":"10.2337\/dc20-1675","volume":"44","author":"SE Inzucchi","year":"2021","unstructured":"Inzucchi SE, et al. Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and reduced ejection fraction: an exploratory analysis from DAPA-HF. Diabetes Care. 2021;44(2):586\u201394.","journal-title":"Diabetes Care"},{"issue":"8","key":"681_CR28","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/dom.12670","volume":"18","author":"F Zaccardi","year":"2016","unstructured":"Zaccardi F, et al. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18(8):783\u201394.","journal-title":"Diabetes Obes Metab"},{"key":"681_CR29","unstructured":"Agency EM. Wegovy - European Medicines Agency. 2023; Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/wegovy"},{"issue":"9","key":"681_CR30","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1111\/dom.12932","volume":"19","author":"J Blundell","year":"2017","unstructured":"Blundell J, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242\u201351.","journal-title":"Diabetes Obes Metab"},{"key":"681_CR31","doi-asserted-by":"crossref","unstructured":"Gabery S et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5(6):e133429.","DOI":"10.1172\/jci.insight.133429"},{"key":"681_CR32","doi-asserted-by":"crossref","unstructured":"Saha B, Kamalumpundi V, Codipilly DC. GLP1 and GIP receptor agonists: effects on the Gastrointestinal tract and management strategies for primary care physicians. Mayo Clin Proc. 2025.","DOI":"10.1016\/j.mayocp.2025.09.017"},{"issue":"10148","key":"681_CR33","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","volume":"392","author":"PM O\u2019Neil","year":"2018","unstructured":"O\u2019Neil PM, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392(10148):637\u201349.","journal-title":"Lancet"},{"issue":"11","key":"681_CR34","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, et al. Once-Weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002.","journal-title":"N Engl J Med"},{"issue":"8","key":"681_CR35","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","volume":"24","author":"JPH Wilding","year":"2022","unstructured":"Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553\u201364.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"681_CR36","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S2213-8587(23)00388-1","volume":"12","author":"Y Mu","year":"2024","unstructured":"Mu Y, et al. Efficacy and safety of once weekly semaglutide 2.4\u00a0mg for weight management in a predominantly East Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2024;12(3):184\u201395.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"14","key":"681_CR37","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403\u201313.","journal-title":"JAMA"},{"issue":"14","key":"681_CR38","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414\u201325.","journal-title":"JAMA"},{"issue":"10","key":"681_CR39","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083\u201391.","journal-title":"Nat Med"},{"issue":"3","key":"681_CR40","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","volume":"10","author":"T Kadowaki","year":"2022","unstructured":"Kadowaki T, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an East Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022;10(3):193\u2013206.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"681_CR41","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138\u201350.","journal-title":"JAMA"},{"issue":"17","key":"681_CR42","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","volume":"391","author":"H Bliddal","year":"2024","unstructured":"Bliddal H, et al. Once-Weekly semaglutide in persons with obesity and knee osteoarthritis. N Engl J Med. 2024;391(17):1573\u201383.","journal-title":"N Engl J Med"},{"issue":"9","key":"681_CR43","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S2213-8587(24)00182-7","volume":"12","author":"BM McGowan","year":"2024","unstructured":"McGowan BM, et al. Efficacy and safety of once-weekly semaglutide 2.4\u00a0mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. Lancet Diabetes Endocrinol. 2024;12(9):631\u201342.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"681_CR44","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1002\/oby.23808","volume":"31","author":"AS Kelly","year":"2023","unstructured":"Kelly AS, et al. Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4\u00a0mg. Obes (Silver Spring). 2023;31(8):2139\u201349.","journal-title":"Obes (Silver Spring)"},{"issue":"10278","key":"681_CR45","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, et al. Semaglutide 2.4\u00a0mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971\u201384.","journal-title":"Lancet"},{"issue":"9","key":"681_CR46","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.2337\/dc19-0749","volume":"42","author":"VR Aroda","year":"2019","unstructured":"Aroda VR, et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42(9):1724\u201332.","journal-title":"Diabetes Care"},{"issue":"12","key":"681_CR47","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.2337\/dc19-0883","volume":"42","author":"HW Rodbard","year":"2019","unstructured":"Rodbard HW, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019;42(12):2272\u201381.","journal-title":"Diabetes Care"},{"issue":"15","key":"681_CR48","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1001\/jama.2019.2942","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with Metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019;321(15):1466\u201380.","journal-title":"JAMA"},{"issue":"7","key":"681_CR49","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S2213-8587(19)30194-9","volume":"7","author":"TR Pieber","year":"2019","unstructured":"Pieber TR, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):528\u201339.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"681_CR50","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.2337\/dc19-0898","volume":"42","author":"B Zinman","year":"2019","unstructured":"Zinman B, et al. Efficacy, Safety, and tolerability of oral semaglutide versus placebo added to insulin with or without Metformin in patients with type 2 diabetes: the PIONEER 8 trial. Diabetes Care. 2019;42(12):2262\u201371.","journal-title":"Diabetes Care"},{"key":"681_CR51","doi-asserted-by":"crossref","unstructured":"Salvador R, et al. Semaglutide as a GLP-1 agonist: A breakthrough in obesity treatment. Pharmaceuticals (Basel). 2025;18:3.","DOI":"10.3390\/ph18030399"},{"issue":"Supplement1","key":"681_CR52","doi-asserted-by":"publisher","first-page":"A16","DOI":"10.1210\/jendso\/bvab048.030","volume":"5","author":"JP Wilding","year":"2021","unstructured":"Wilding JP, et al. Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study. J Endocr Soc. 2021;5(Supplement1):A16\u20137.","journal-title":"J Endocr Soc"},{"issue":"2","key":"681_CR53","doi-asserted-by":"publisher","first-page":"S145","DOI":"10.2337\/dcS13-2015","volume":"36","author":"MY Donath","year":"2013","unstructured":"Donath MY, Burcelin R. GLP-1 effects on islets: hormonal, neuronal, or paracrine? Diabetes Care. 2013;36(2):S145\u20138.","journal-title":"Diabetes Care"},{"issue":"5","key":"681_CR54","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.diabet.2018.12.001","volume":"45","author":"VR Aroda","year":"2019","unstructured":"Aroda VR, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1\u20137 trials. Diabetes Metab. 2019;45(5):409\u201318.","journal-title":"Diabetes Metab"},{"issue":"11","key":"681_CR55","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","volume":"7","author":"I Lingvay","year":"2019","unstructured":"Lingvay I, et al. Efficacy and safety of once-weekly semaglutide versus daily Canagliflozin as add-on to Metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(11):834\u201344.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"681_CR56","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","volume":"7","author":"B Zinman","year":"2019","unstructured":"Zinman B, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(5):356\u201367.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"681_CR57","doi-asserted-by":"publisher","first-page":"p100","DOI":"10.1016\/j.diabet.2019.101117","volume":"46","author":"MS Capehorn","year":"2020","unstructured":"Capehorn MS, et al. Efficacy and safety of once-weekly semaglutide 1.0\u00a0mg vs once-daily liraglutide 1.2\u00a0mg as add-on to 1\u20133 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46(2):p100\u2013109.","journal-title":"Diabetes Metab"},{"issue":"9","key":"681_CR58","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1111\/dom.14765","volume":"24","author":"M Kellerer","year":"2022","unstructured":"Kellerer M, et al. Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to Metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial. Diabetes Obes Metab. 2022;24(9):1788\u201399.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"681_CR59","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S2213-8587(21)00174-1","volume":"9","author":"JP Frias","year":"2021","unstructured":"Frias JP, et al. Efficacy and safety of once-weekly semaglutide 2.0\u00a0mg versus 1.0\u00a0mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol. 2021;9(9):563\u201374.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10192","key":"681_CR60","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","volume":"394","author":"R Pratley","year":"2019","unstructured":"Pratley R, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394(10192):39\u201350.","journal-title":"Lancet"},{"issue":"7","key":"681_CR61","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","volume":"7","author":"O Mosenzon","year":"2019","unstructured":"Mosenzon O, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):515\u201327.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"681_CR62","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841\u201351.","journal-title":"N Engl J Med"},{"key":"681_CR63","doi-asserted-by":"crossref","unstructured":"Buse JB et al. Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial. BMJ Open Diabetes Res Care. 2020;8(2):e001649.","DOI":"10.1136\/bmjdrc-2020-001649"},{"issue":"5","key":"681_CR64","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S2213-8587(20)30075-9","volume":"8","author":"Y Yamada","year":"2020","unstructured":"Yamada Y, et al. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2\/3a, randomised, controlled trial. Lancet Diabetes Endocrinol. 2020;8(5):377\u201391.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"681_CR65","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S2213-8587(20)30074-7","volume":"8","author":"D Yabe","year":"2020","unstructured":"Yabe D, et al. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2020;8(5):392\u2013406.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"681_CR66","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1007\/s00125-024-06142-3","volume":"67","author":"W Wang","year":"2024","unstructured":"Wang W, et al. Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, phase IIIa, randomised trial. Diabetologia. 2024;67(9):1783\u201399.","journal-title":"Diabetologia"},{"issue":"9","key":"681_CR67","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1007\/s00125-024-06133-4","volume":"67","author":"L Ji","year":"2024","unstructured":"Ji L, et al. Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, phase IIIa, randomised trial. Diabetologia. 2024;67(9):1800\u201316.","journal-title":"Diabetologia"},{"issue":"10403","key":"681_CR68","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S0140-6736(23)01127-3","volume":"402","author":"VR Aroda","year":"2023","unstructured":"Aroda VR, et al. Efficacy and safety of once-daily oral semaglutide 25\u00a0mg and 50\u00a0mg compared with 14\u00a0mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial. Lancet. 2023;402(10403):693\u2013704.","journal-title":"Lancet"},{"issue":"1","key":"681_CR69","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","volume":"21","author":"MA Nauck","year":"2022","unstructured":"Nauck MA, D\u2019Alessio DA. Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022;21(1):169.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"681_CR70","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","volume":"31","author":"RJ Samms","year":"2020","unstructured":"Samms RJ, Coghlan MP, Sloop KW. How May GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab. 2020;31(6):410\u201321.","journal-title":"Trends Endocrinol Metab"},{"key":"681_CR71","doi-asserted-by":"publisher","first-page":"101090","DOI":"10.1016\/j.molmet.2020.101090","volume":"46","author":"LL Baggio","year":"2021","unstructured":"Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. Mol Metab. 2021;46:101090.","journal-title":"Mol Metab"},{"issue":"3","key":"681_CR72","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316.","journal-title":"N Engl J Med"},{"issue":"1","key":"681_CR73","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26\u201336.","journal-title":"N Engl J Med"},{"issue":"6","key":"681_CR74","first-page":"e85531","volume":"17","author":"A Kasagga","year":"2025","unstructured":"Kasagga A, et al. Dose-Dependent efficacy and safety of Tirzepatide for weight loss in Non-diabetic adults with obesity: A systematic review and Meta-analysis of randomized controlled trials. Cureus. 2025;17(6):e85531.","journal-title":"Cureus"},{"issue":"1","key":"681_CR75","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","volume":"331","author":"LJ Aronne","year":"2024","unstructured":"Aronne LJ, et al. Continued treatment with Tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38\u201348.","journal-title":"JAMA"},{"issue":"10295","key":"681_CR76","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist Tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143\u201355.","journal-title":"Lancet"},{"issue":"6","key":"681_CR77","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Frias","year":"2021","unstructured":"Frias JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503\u201315.","journal-title":"N Engl J Med"},{"issue":"10300","key":"681_CR78","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","volume":"398","author":"B Ludvik","year":"2021","unstructured":"Ludvik B, et al. Once-weekly Tirzepatide versus once-daily insulin degludec as add-on to Metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583\u201398.","journal-title":"Lancet"},{"issue":"10313","key":"681_CR79","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","volume":"398","author":"S Del Prato","year":"2021","unstructured":"Del Prato S, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811\u201324.","journal-title":"Lancet"},{"issue":"17","key":"681_CR80","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1001\/jama.2023.20294","volume":"330","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock J, et al. Tirzepatide vs insulin Lispro added to basal insulin in type 2 diabetes: the SURPASS-6 randomized clinical trial. JAMA. 2023;330(17):1631\u201340.","journal-title":"JAMA"},{"issue":"11","key":"681_CR81","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.2337\/dc23-0872","volume":"46","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock J, et al. Achieving normoglycemia with tirzepatide: analysis of SURPASS 1\u20134 trials. Diabetes Care. 2023;46(11):1986\u201392.","journal-title":"Diabetes Care"},{"issue":"10","key":"681_CR82","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa2410819","volume":"392","author":"AM Jastreboff","year":"2025","unstructured":"Jastreboff AM, et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025;392(10):958\u201371.","journal-title":"N Engl J Med"},{"key":"681_CR83","doi-asserted-by":"crossref","unstructured":"Ortega MA et al. Type 2 diabetes mellitus associated with obesity (Diabesity). The central role of gut microbiota and its translational applications. Nutrients. 2020;12(9):2749.","DOI":"10.3390\/nu12092749"},{"issue":"10","key":"681_CR84","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","volume":"61","author":"MC Thomas","year":"2018","unstructured":"Thomas MC, Cherney DZI. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia. 2018;61(10):2098\u2013107.","journal-title":"Diabetologia"},{"key":"681_CR85","doi-asserted-by":"crossref","unstructured":"Popoviciu MS et al. SGLT-2i-A useful tool for Real-Life metabolic and body weight control in type 2 diabetes mellitus patients. Med (Kaunas). 2025;61(3)548.","DOI":"10.3390\/medicina61030548"},{"key":"681_CR86","doi-asserted-by":"crossref","unstructured":"Salvatore T et al. An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors. Int J Mol Sci. 2022;23(7)3651.","DOI":"10.3390\/ijms23073651"}],"container-title":["Current Obesity Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-025-00681-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13679-025-00681-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-025-00681-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T09:02:19Z","timestamp":1768294939000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13679-025-00681-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["681"],"URL":"https:\/\/doi.org\/10.1007\/s13679-025-00681-5","relation":{},"ISSN":["2162-4968"],"issn-type":[{"value":"2162-4968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"1 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}